Navigation Links
StockCall Research on Boston Scientific and Medtronic: Focus on Paroxysmal Atrial Fibrillation
Date:1/22/2013

LONDON, January 22, 2013 /PRNewswire/ --

The medical appliances and equipment industry faced its fair share of challenges during the recession, as procedural volume in some cases was reduced due to the economic situation in the U.S. and Europe. Analysts from our services research team completed in-depth analysis on Boston Scientific Corporation (NYSE: BSX) and Medtronic Inc. (NYSE: MDT). These free reports are available at

http://www.stockcall.com/registration    

Competition also crimped margins for several companies, leading to lower sales and profits. However, with the recession in the rear view mirror, the outlook for the industry and companies such as Boston Scientific and Medtronic is positive. Now that companies have been afforded some breathing room, they are focusing their attentions on bringing new products to market and growing their international footprint. Download the free report on Scientific by signing up now at

http://www.StockCall.com/BSX012213.pdf

Both Boston Scientific and Medtronic [Free Report on MDT][1] have been looking to new products to grow their top- and bottom-lines, and both have recently been involved with paroxysmal atrial fibrillation. Atrial fibrillation affects around 15 million people globally, and can cause serious health problems such as strokes and heart failure.

In the case of Boston Scientific, the company newly announced that the first patient has been treated in its ZERO AF clinical trial. The results of the trial are anticipated to be used to back up an FDA regulatory submission for a paroxysmal atrial fibrillation indication.

Medtronic has als
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation
2. Russian Government Starts Using Scopus for National Research Assessment
3. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
4. US Vitamin injections Posts New Research Involving B Vitamin Deficiency
5. Maximizing the Effectiveness of Market Research Groups through Outsourcing and Automation
6. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
7. BodyMedia Collaborates on Federal Health Research Study
8. Genomic Research Service Provider DNA Link Purchases 10 Ion Proton Sequencers
9. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
10. Seahorse Bioscience Announces Asia Mito 2012 Travel Award Winners Advancing Cell Metabolism Research
11. German Cancer Research Center Selects Contur ELN from Accelrys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014 Research ... "PCSK9 and Other Novel Hypercholesterolemia Drugs" report ... that there is a high cholesterol burden despite the ... of all the available options, statins have been ubiquitously ... that reduction of plasma LDL cholesterol (LDLC) is the ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  Elusys ... therapies to treat infectious disease, today announced it ... safety studies of obiltoxaximab (ETI-204). Obiltoxaximab is an ... anthrax and data from these studies support the ... intravenously (IV) at the intended therapeutic dose. The ...
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
Breaking Medicine Technology:PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... Feb. 23, 2011 Plexus Biomedical Inc. has been ... and Drug Administration to market the first device clinically ... Hemorrhoids associated with vaginal delivery are a frequent complication ... women in the U.S. every year. The ...
... Inc. (Nasdaq: MAPP ) today announced that the ... Citi,s 2011 Global Healthcare Conference , Wednesday, March 2, at ... , Thursday, March 3, at 10:00 a.m. ET in ... March 9, at 10:15 a.m. ET in BostonBarclays Capital 2011 ...
Cached Medicine Technology:Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth 2
(Date:9/22/2014)... September 22, 2014 WHO: LiveOps, ... and customer service solutions. , WHAT: The 10th ... on customer care for the connected consumer. Constant ... to offer new challenges and opportunities for customer ... attendees identify best practices, network and learn from ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... Tara Haelle ... News) -- Measuring how quickly a child,s brain processes ... to a new study. Observing children,s brainwaves ... currently possible, the study authors reported. "The finding ... is associated with autism severity is hugely promising," said ...
(Date:9/22/2014)... September 22, 2014 The “ Ztylus ” ... Tech Report , which reviews and features the latest technology ... of NewsWatch and technology expert, conducted the review and shared ... snap-in lens kit that gives users four lens options for ... part of its monthly Tech Report, which reviews and features ...
(Date:9/22/2014)... Medical experts this past weekend gathered ... discuss brain-related diseases facing an aging population, including ... disorders. , Each of the 50 attendees ... memory care community or hospice office. Silverado, with ... hosts the annual event to facilitate the exchange ...
Breaking Medicine News(10 mins):Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... receive fewer blood transfusions do just as well as those ... of blood transfusions varies widely among U.S. hospitals. The ... Journal of the American Medical Association . In ...
... murine leukemia virusrelated virus (XMRV) has been the subject ... conflicting reports have created an unclear picture of XMRV,s ... in the November 15 issue of The Journal ... supports a possible link between XMRV and prostate cancer ...
... molecule they designed can block activation of a gene in ... those cancer cells to survive chemotherapy. Without the ... to be protected from the toxic effects of chemotherapy drugs. ... protecting the cells, the research suggests. As a result, more ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Oct. ... cancer patients treated with bisphosphonate drugs such as Aredia or ... be at higher risk for the irregular heartbeat known as ... atrial fibrillation, the upper chambers of the heart beat chaotically, ...
... results of a large Phase-III clinical trial have shown ... with a hard-to-treat group of rare cancers that affect ... the European Society for Medical Oncology (ESMO), Dr Marianne ... everolimus improved progression-free survival by 5.1 months in patients ...
... of breast cancer can lead some women to wonder if ... of more than 85,000 postmenopausal women, published in BioMed Central,s ... regular physical activity, maintaining a healthy weight, and drinking less ... a family history of the disease. The University of ...
Cached Medicine News:Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 2Health News:Cancer-Fighting Bone Drugs Might Raise Stroke Risk 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
... ChartingPlus proves itself to over 2,000 medical ... with the user in mind, ChartingPlus relies ... and dynamic features to improve documentation quality ... Our medical content is specific ...
Medicine Products: